Trial · NCT02181738
Adverse events3,570
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 3,570
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin- Nivolumab 3 mg/kg | 4 | 46 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin-Nivolumab 240 mg | 1 | 9 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin-Nivolumab 480 mg | 1 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Stem Cell Transplant-Nivolumab 3 mg/kg | 12 | 75 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Stem Cell Transplant-Nivolumab 240 mg | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Stem Cell Transplant- Nivolumab 480 mg | 0 | 2 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort C: Post Transplant, Brentuximab Vedotin Pre-and/or Post-SC Transplant - Nivolumab 3 mg/kg | 18 | 84 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort C: Post Transplant, Brentuximab Vedotin Pre-and/Post-Stem Cell Transplant - Nivolumab 240 mg | 2 | 13 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort C: Post Transplant, Brentuximab Vedotin Pre-and/Post-Stem Cell Transplant - Nivolumab 480 mg | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV) | 9 | 51 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin- Nivolumab 3 mg/kg | 1 | 46 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin-Nivolumab 240 mg | 0 | 9 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin-Nivolumab 480 mg | 1 | 8 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Stem Cell Transplant-Nivolumab 3 mg/kg | 0 | 75 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Stem Cell Transplant-Nivolumab 240 mg | 0 | 3 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Stem Cell Transplant- Nivolumab 480 mg | 0 | 2 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort C: Post Transplant, Brentuximab Vedotin Pre-and/or Post-SC Transplant - Nivolumab 3 mg/kg | 0 | 84 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort C: Post Transplant, Brentuximab Vedotin Pre-and/Post-Stem Cell Transplant - Nivolumab 240 mg | 0 | 13 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort C: Post Transplant, Brentuximab Vedotin Pre-and/Post-Stem Cell Transplant - Nivolumab 480 mg | 0 | 3 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Cohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV) | 0 | 51 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02181738/events